The Pharma Data

JULY 27, 2021

Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. About Teneobio Teneobio, Inc. Our business may be impacted by government investigations, litigation and product liability claims.

Production 52

Production Clinical Trials Government Disease 52

DrugBank

FEBRUARY 12, 2025

In Silico Drug Repurposing Advances in bioinformatics and systems biology have fueled the rise of repurposing of in silico drugs. Thalidomide : Initially marketed as a sedative in the late 1950s, thalidomide was withdrawn from the market due to its severe teratogenic effects.

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

The Pharma Data

DECEMBER 16, 2020

This includes Evotec’s data analysis platform “PanHunter”, a proprietary, integrated, user-centred bioinformatics platform which facilitates the analysis of PanOmics data integrated with other metadata sets. 0)40.56081-255, gabriele.hansen@evotec.com. 0)40.56081-775, volker.braun@evotec.com.

Targeted Protein Degradation 40

Targeted Protein Degradation Bioinformatics Disease Drugs 40

The Pharma Data

DECEMBER 8, 2020

Orphan drug designation is the first step in receiving orphan drug exclusivity following approval, which confers seven years of market exclusivity for the relevant indication. The granting of an orphan drug designation request does not alter the standard regulatory requirements and process for obtaining marketing approval.

FDA 40

FDA Treatment Drugs FDA Approval 40

BMG Labtech

OCTOBER 4, 2023

2 DNA sequencing is also reliant on sample processing and DNA library preparation before sequencing as well as bioinformatics and data analysis after sequencing. Illumina’s sequencers are powered by its proven sequencing-by-synthesis (SBS) technologies and still have a significant part of the market but face increasing competition.

DNA 52

DNA RNA Bioinformatics Research 52

DrugBank

MARCH 15, 2023

In addition to our talented medical experts, who work tirelessly to ensure that our drug knowledgebase is the most accurate, up-to-date, and usable on the market, we have a versatile customer team that is singularly focused on making your work with us as easy and effective as possible.

Licensing 52

Licensing Licensing International Bioinformatics 52

The Open Targets Blog

APRIL 25, 2023

Bioinformatics, Volume 13, Issue 4, August 1997, Pages 333–344 9. Bear market slashes at human genome. Comput Appl Biosci 13, 523–535 (1997). Searls, D.B. Linguistic approaches to biological sequences. The Intelligence Factory. Bletchley Park 10. Powledge, T. EMBO reports 1, 212–214 (2000). The gene guessing game.

DNA 52

DNA Government Engineering Laboratories 52

The Pharma Data

JANUARY 10, 2021

I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. Moving on From the Amyloid Hypothesis. “I The future of cancer prevention?

Vaccine 52

Vaccine Disease Regulations Small Molecule 52

The Pharma Data

OCTOBER 27, 2020

The decrease in Adcirca revenues was driven by continued erosion of market share due to generic competition. Sales and marketing. Cash, cash equivalents, and marketable investments. Cost of product sales. Dollar Change. .

FDA 40

FDA Production Licensing Licensing 40

The Pharma Data

SEPTEMBER 1, 2020

Presentation Topic: Biomarkers and Bioinformatics. Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials. Author: Harris. Presentation Number: P0118. Author: Healy. Presentation Number: P1010. No forward-looking statement can be guaranteed.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

Drug Target Review

FEBRUARY 11, 2025

Given that only a fraction of early-stage drug candidates progress to market, the costs associated with these failures are inevitably absorbed into the overall development costs. The recognised mutation-treatment interactions can help select patients for clinical trials and define treatments for patients that are already on the market.

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59

Drug Target Review

MARCH 13, 2025

The operational impact of xAI is substantial, especially given that 37 percent of the market views the explanation of results from GenAI algorithms as a strategic priority that goes beyond regulatory compliance. He holds a masters degree from University of Salerno in political sciences and marketing.

Drug Development 59

Drug Development Clinical Trials Science FDA 59